HN2011001446A - Compuesto utiles para inhibir chk1 - Google Patents

Compuesto utiles para inhibir chk1

Info

Publication number
HN2011001446A
HN2011001446A HN2011001446A HN2011001446A HN2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A HN 2011001446 A HN2011001446 A HN 2011001446A
Authority
HN
Honduras
Prior art keywords
compound useful
inhibit chk1
chk1
inhibit
useful
Prior art date
Application number
HN2011001446A
Other languages
English (en)
Inventor
Farouz Francine
Kasar Ramesh
Coast Orth Holcomb Ryan
Scott Myers Steven
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HN2011001446A publication Critical patent/HN2011001446A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN COMPUESTO DE AMINOPIRAZOL O UNA SAL DEL MISMO FARMACEUTICAMENTE ACEPTABLE O UN SOLVATO DE LA SAL, QUE INHIBE A CHK 1 Y ES UTIL PARA TRATAR CANCERES, CARACTERIZADO POR DEFECTOS EN REPLICACION DE ACIDO DESOXIRRIBONUCLEICO (ADN) SEGREGACION DE CROMOSOMAS O DIVISION CELULAR.
HN2011001446A 2008-12-17 2011-06-01 Compuesto utiles para inhibir chk1 HN2011001446A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
HN2011001446A true HN2011001446A (es) 2013-08-05

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2011001446A HN2011001446A (es) 2008-12-17 2011-06-01 Compuesto utiles para inhibir chk1

Country Status (38)

Country Link
EP (1) EP2379532B1 (es)
JP (1) JP5705743B2 (es)
KR (1) KR101301777B1 (es)
CN (1) CN102245597B (es)
AR (1) AR074471A1 (es)
AU (1) AU2009333433B2 (es)
BR (1) BRPI0922468A2 (es)
CA (1) CA2746423C (es)
CL (1) CL2011001463A1 (es)
CO (1) CO6382122A2 (es)
CR (1) CR20110339A (es)
CY (1) CY1113930T1 (es)
DK (1) DK2379532T3 (es)
DO (1) DOP2011000185A (es)
EA (1) EA018118B1 (es)
EC (1) ECSP11011136A (es)
ES (1) ES2401558T3 (es)
HK (1) HK1160110A1 (es)
HN (1) HN2011001446A (es)
HR (1) HRP20130167T1 (es)
IL (1) IL213160A (es)
JO (1) JO2886B1 (es)
MA (1) MA32901B1 (es)
MX (1) MX2011006603A (es)
MY (1) MY156998A (es)
NZ (1) NZ593440A (es)
PA (1) PA8850801A1 (es)
PE (1) PE20120077A1 (es)
PL (1) PL2379532T3 (es)
PT (1) PT2379532E (es)
RS (1) RS52739B (es)
SG (1) SG172222A1 (es)
SI (1) SI2379532T1 (es)
TN (1) TN2011000298A1 (es)
TW (1) TWI436996B (es)
UA (1) UA101998C2 (es)
WO (1) WO2010077758A1 (es)
ZA (1) ZA201103946B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
AR083575A1 (es) * 2010-11-08 2013-03-06 Lilly Co Eli Aminopirazoles para inhibir la proteinquinasa chk1
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
NZ742470A (en) * 2015-12-15 2019-09-27 Lilly Co Eli Combination therapy for cancer
CN108601781B (zh) 2016-02-04 2019-11-22 广州必贝特医药技术有限公司 作为检测点激酶1(chk1)抑制剂的3,5-二取代吡唑及其制备及应用
EP3600247A1 (en) 2017-03-31 2020-02-05 Seattle Genetics, Inc. Combinations of chk1- and wee1 - inhibitors
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP4067351A4 (en) * 2019-11-29 2023-11-22 Medshine Discovery Inc. DIAZAINDOLE DERIVATIVE AND ITS USE AS CHK1 INHIBITOR
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
CA3200498A1 (en) 2020-11-30 2022-06-02 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1h-pyrazol-3-amine derivative
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
CN117715905A (zh) 2021-05-27 2024-03-15 无界生物公司 检查点激酶1（chk1）抑制剂及其用途
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
TW202333680A (zh) * 2021-12-24 2023-09-01 日商住友製藥股份有限公司 具有二環性骨架之1h-吡唑-3-胺衍生物
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
JO2886B1 (en) 2015-03-15
JP2012512249A (ja) 2012-05-31
SG172222A1 (en) 2011-07-28
IL213160A (en) 2013-12-31
TW201029994A (en) 2010-08-16
RS52739B (en) 2013-08-30
CL2011001463A1 (es) 2012-01-20
HRP20130167T1 (hr) 2013-03-31
CY1113930T1 (el) 2016-07-27
WO2010077758A1 (en) 2010-07-08
AU2009333433B2 (en) 2012-06-14
MX2011006603A (es) 2011-09-27
UA101998C2 (ru) 2013-05-27
ZA201103946B (en) 2012-10-31
PL2379532T3 (pl) 2013-07-31
ECSP11011136A (es) 2011-07-29
CA2746423C (en) 2014-01-14
IL213160A0 (en) 2011-07-31
PT2379532E (pt) 2013-03-25
KR20110084539A (ko) 2011-07-25
BRPI0922468A2 (pt) 2020-08-04
PE20120077A1 (es) 2012-02-06
TWI436996B (zh) 2014-05-11
CN102245597B (zh) 2014-04-16
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
HK1160110A1 (en) 2012-08-10
DK2379532T3 (da) 2013-03-18
JP5705743B2 (ja) 2015-04-22
AR074471A1 (es) 2011-01-19
ES2401558T3 (es) 2013-04-22
CA2746423A1 (en) 2010-07-08
EP2379532B1 (en) 2013-02-20
MA32901B1 (fr) 2011-12-01
CR20110339A (es) 2011-09-14
EP2379532A1 (en) 2011-10-26
MY156998A (en) 2016-04-15
CN102245597A (zh) 2011-11-16
CO6382122A2 (es) 2012-02-15
PA8850801A1 (es) 2010-07-27
KR101301777B1 (ko) 2013-08-30
EA201170834A1 (ru) 2011-12-30
DOP2011000185A (es) 2017-12-15
SI2379532T1 (sl) 2013-05-31
AU2009333433A1 (en) 2011-06-30
EA018118B1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
HN2011001446A (es) Compuesto utiles para inhibir chk1
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CR20110257A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
GT200800158A (es) Pirazolquinolonas como potentes inhibidores de parp
BRPI0717125B8 (pt) Composto derivado de ftalazinona como forma cristalina a, métodos para obter o mesmo e usos terapêuticos do dito composto
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY32045A (es) Compuesto amida
ECSP13012420A (es) Derivados de tetrahidro-pirido-pirimidina
HN2008001374A (es) Compuestos de cinamida policiclicos
SV2011003855A (es) Heteroarilos sustituidos
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
EA201071144A1 (ru) Гетероциклические производные
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
MX2009011749A (es) Compuestos triciclicos como inhibidores de metaloproteinasa matricial.
UY32153A (es) Inhibidores de piridomidinona de pi13ka(alfa) y mtor
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
NO20084301L (no) Tetrahydronaftalenderivater, fremgangsmate for deres fremstilling og anvendelse derav som anti-inflammatoriske midler
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
BR112012008017A2 (pt) 1,2,4-triazina, utilização de uma 1,2,4-triazina e processo de preparação de uma 1,2,4-triazina